天士力

600535.SH

Wind Industry: 医疗保健 > 医药生物 > 制药 > 中药

公司是以大健康产业为主线，以生物医药产业为核心，以健康产业和医疗康复、健康养生、健康管理为两翼的高科技国际化企业集团，是天津市重点支持的大企业集团之一，主营现代中药、化学药等的科研、种植、提取、销售等。公司自行研制成功具有国际先进水平的大型自动化滴丸生产线，主导产品复方丹参滴丸以药品身份进入韩国、越南等国家和地区的医药市场，在马来西亚、南非等国家地区建立公司，形成了多层次的营销体系。公司致力于打造符合系列标准的一体化现代中药产业链，率先建立了现代中药和植物药提取生产质量管理规范(GEP)，建立了通过国家药品生产质量管理规范(GMP)认证的现代中药生产基地。

ESG Score Industry Ranking:
1 / 282 (制药)

ESG Rating Distribution(制药)

0.35%

AAA

2.84%

17.73%

20.21%

BBB

30.14%

24.11%

0.35%

CCC

Trend of Rating

About Wind ESG Rating

Wind has developed a rigorous rating methodology based on the core connotations of ESG, aligning with international standards and frameworks, and incorporating the characteristics of Chinese companies, to assess the company's essential ESG performance, risk and its ability to operate sustainably.

Focusing on the ESG risks and opportunities of each industry, the companies are rated on a AAA-CCC scale relative to the performance of their industry peers. Wind ESG rating is updated annually or in response to major changes.

The Wind ESG Rating Issuer Communication Platform (esg.wind.com.cn) is now available. Rated companies can access their detailed rating information through this platform, and communicate with or provide feedback to the Wind ESG Rating team regarding specific rating components. For any additional questions, please feel free to send an email to GR.ESG@wind.com.cn.

ESG Score

ESG Score：8.94Updated on 2026-10-29

08.9410

Management & Practices Score：5.94Updated on 2026-10-14

05.947

Controversies Score：3.00Updated on 2026-10-29

03.003

ESG Score Comparison

Indicator	Company Score	Industry Average	Weight
Environmental	9.07	3.56	22.85%
Social	8.63	3.72	49.76%
Governance	7.75	5.34	27.39%

Wind ESG Rating Framework

Building on the foundation of domestic and international ESG policies and standards, our proprietary ESG rating framework considers the development of Chinese capital market and integrates the characteristics of the Chinese companies in various industries. The Wind ESG Rating framework is composed of management & practice and controversies assessment, including:

500+ management & practices indicators, covering E, S and G pillars, reflecting long-term ESG fundamental impacts
1,200+ risk labels, covering news, regulatory penalties and lawsuits, reflecting impact of short-term risks

Management & practice score is the weighted summation of E, S and G pillar scores. The weights reflect both the relative impact of each issue within each industry and the negative or positive contribution of each industry to the environment and society relative to other industries.

Controversies score and ESG score are updated daily, E, S and G pillar scores and management & practice score are updated with underlying data, corresponding data are released on various channels, including Wind Financial Terminal.

Explore More

Wind ESG Rating Methodology.pdf1,198KB Wind ESG Ratings FAQs.pdf755KB

More Details

Peer Comparison(282 companies in the industry) ?

Ranking	Code	Security Name	ESG Rating	ESG Score	Controversies Score	Management & Practices Score	Environmental	Social	Governance
1	600535.SH	天士力	AAA	8.94	3.00	5.94	9.07	8.63	7.75
2	301130.SZ	西点药业	AA	8.39	3.00	5.39	7.28	7.78	7.92
3	3320.HK	华润医药	AA	8.31	3.00	5.31	7.23	7.73	7.62
4	600380.SH	健康元	AA	8.22	3.00	5.22	5.64	8.16	7.66
5	603896.SH	寿仙谷	AA	8.18	3.00	5.18	6.54	7.51	7.92
6	600329.SH	达仁堂	AA	8.15	3.00	5.15	6.24	7.44	8.16
7	601607.SH	上海医药	AA	8.07	3.00	5.07	7.19	7.17	7.40
8	000999.SZ	华润三九	AA	8.03	3.00	5.03	7.66	7.39	6.42
9	301281.SZ	科源制药	A	7.99	2.99	4.99	5.58	7.51	7.72
10	000513.SZ	丽珠集团	AA	7.94	2.99	4.94	5.51	7.94	6.76